ClinicalTrials.gg
Active, not recruitingNCT06483334Updated Feb 18, 2026

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

A Phase 1/2 interventional study of Sacituzumab tirumotecan and Enfortumab Vedotin in Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 25 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell — 10 open to participants now, 15 under way, 1 of them phase 3. enfortumab vedotin · Carcinoma, Transitional Cell.

Planned enrollment
12th of 20
38 · median 49
Started
2024
the only one that year
Phase 1/2
4 of 20
1 open now
Primary completion
2028-03
later than 7 of 14 live
Registered
12th of 20
by date
Lead sponsor
1 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, this one is the 12th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 1/2, reaches primary completion later than 7 of the 14 other live ones, and was the 12th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

10 of the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About enfortumab vedotin

enfortumab vedotin: first FDA approval 2019 (PADCEV), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.

Read the detailed description

The master study for this substudy is MK-3475-U04/KEYMAKER-U04. The master study will not be screening any participants and will not be registered.

As of Amendment 5, Part 2 will not be conducted. No participants will be enrolled in Part 2, and no data for Part 2 will be collected.

03

Conditions studied

  • Metastatic Urothelial Carcinoma
  • Locally Advanced Urothelial Carcinoma

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Must have documented, locally advanced/ urothelial carcinoma (la/mUC).
  • Must provide an sample or newly obtained core or excisional biopsy of a tumor lesion demonstrating UC, not previously irradiated, and adequate for biomarker evaluation. A newly obtained biopsy is strongly preferred, but not required if archival tissue is evaluable.
  • Any AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Endocrine-related AEs adequately treated with hormone replacement are eligible.
  • PART 1 ONLY: Participants must have received platinum-based chemotherapy for treatment of la/mUC.
  • PART 1 ONLY: Participants must not have received >2 for la/mUC. Platinum-based chemotherapy followed by avelumab maintenance is considered 2 lines of therapy.
  • PART 2 ONLY: Participants must not have received prior systemic therapy for la/mUC.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Known additional that is progressing or has required active treatment within the past 3 years.
  • Known active central nervous system and/or carcinomatous meningitis.
  • Has Grade ≥2 peripheral neuropathy.
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease and/or serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention.
  • Has active keratitis or corneal ulcerations. Superficial punctate keratitis is allowed if the disorder is being adequately treated in the opinion of the investigator.
  • Has a history of uncontrolled diabetes.
  • Has received an agent or has used an investigational device within 4 weeks prior to study intervention administration.
  • Has received a live or within 30 days prior to the first dose of study intervention.
  • PART 2 ONLY: Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention. Inhaled or topical steroids are permitted in the absence of active disease. Physiologic replacement doses of corticosteroids are permitted for participants with adrenal insufficiency.
  • PART 2 ONLY: Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy.
  • Is (HIV)-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
  • Has active or virus infection.
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Has an active infection requiring systemic therapy.
  • PART 2 ONLY: History of allogeneic tissue/solid organ transplant.
  • Has not adequately recovered from major surgery or has ongoing surgical complications.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Sacituzumab tirumotecan plus EV

    Participants will receive sacituzumab tirumotecan as an intravenous (IV) infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision.

    Biological: Sacituzumab tirumotecan · Biological: Enfortumab Vedotin · Drug: Supportive care measures

  • Experimental
    Sacituzumab tirumotecan plus EV and pembrolizumab

    Participants will receive sacituzumab tirumotecan as an IV infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision. Participants will also receive pembrolizumab 200 mg as an IV infusion on Day 1 of every 3-week cycle for up to \~2 years (35 cycles).

    Biological: Sacituzumab tirumotecan · Biological: Enfortumab Vedotin · Biological: Pembrolizumab · Drug: Supportive care measures

Interventions

  • IV infusion at different dose levels

    Also known as: MK-2870, SKB264

  • IV infusion at different dose levels

    Also known as: PADCEV™

  • BiologicalPembrolizumab

    200 mg IV infusion

    Also known as: MK-3475, KEYTRUDA

  • DrugSupportive care measures

    Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions.

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants with Dose-limiting toxicities (DLT)

    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE 5.0). The number of participants who experience a DLT in Part 1 will be reported.

    Time frame: Up to 21 days

  2. Part 1: Percentage of Participants Who Experienced At Least One Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants experiencing an AE in Part 1 will be reported.

    Time frame: Up to ~3 years

  3. Part 1: Percentage of Participants Who Discontinued Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants who discontinue study treatment due to an AE in Part 1 will be reported.

    Time frame: Up to ~2 years

  4. Part 2: Percentage of Participants with DLT

    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the NCI CTCAE 5.0. The number of participants who experience a DLT in Part 2 will be reported.

    Time frame: Up to 21 days

  5. Part 2: Percentage of Participants Who Experienced At Least One AE

    An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants experiencing an AE in Part 2 will be reported.

    Time frame: Up to ~3 years

  6. Part 2: Percentage of Participants Who Discontinued Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of participants who discontinue study treatment due to an AE in Part 2 will be reported.

    Time frame: Up to ~2 years

  7. Part 2: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve a confirmed complete response (CR) (disappearance of all target lesions) or partial response (PR) (at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator. ORR will be reported for participants in Part 2.

    Time frame: Up to ~3 years

Secondary outcomes

  1. Part 1: ORR

    ORR is defined as the percentage of participants who achieve a confirmed CR or PR per RECIST 1.1 as assessed by investigator. ORR will be reported for participants in Part 1.

    Time frame: Up to ~3 years

  2. Part 2: Duration of Response (DOR)

    For participants who demonstrate confirmed CR or PR per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by investigator will be presented.

    Time frame: Up to ~3 years

  3. Part 1: Maximum Serum Concentration (Cmax) of Sacituzumab Tirumotecan-Antibody-Drug Conjugate (ADC)

    Blood samples collected at designated time points will be used to determine the Cmax of sacituzumab tirumotecan-ADC in Part 1.

    Time frame: Days 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, Day 1 of Cycles 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  4. Part 1: Serum Trough Concentration (Ctrough) of Sacituzumab Tirumotecan-ADC

    Blood samples collected at designated time points will be used to determine the Ctrough of sacituzumab tirumotecan-ADC in Part 1.

    Time frame: Days 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, Day 1 of Cycles 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  5. Part 1: Cmax of Free Payload for Sacituzumab Tirumotecan

    Blood samples collected at designated time points will be used to determine the Cmax of free payload for sacituzumab tirumotecan in Part 1.

    Time frame: Days 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, Day 1 of Cycles 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  6. Part 1: Ctrough of Free Payload for Sacituzumab Tirumotecan

    Blood samples collected at designated time points will be used to determine the Ctrough of free payload for sacituzumab tirumotecan in Part 1.

    Time frame: Days 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, Day 1 of Cycles 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  7. Part 1: Cmax of Enfortumab Vedotin-ADC

    Blood samples collected at designated time points will be used to determine the Cmax of enfortumab vedotin-ADC in Part 1.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, and Day 1 of Cycles 4 and 8

  8. Part 1: Ctrough of Enfortumab Vedotin-ADC

    Blood samples collected at designated time points will be used to determine the Ctrough of enfortumab vedotin-ADC in Part 1.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, and Day 1 of Cycles 4 and 8

  9. Part 1: Cmax of Free Payload for Enfortumab Vedotin

    Blood samples collected at designated time points will be used to determine the Cmax of free payload for EV in Part 1.

    Time frame: Days 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, and Day 1 of Cycles 4 and 8

  10. Part 1: Ctrough of Free Payload for Enfortumab Vedotin

    Blood samples collected at designated time points will be used to determine the Ctrough of free payload for EV in Part 1.

    Time frame: Days 1, 8, 15 of Cycle 1 (each cycle is 21 days), Day 1 of Cycle 2, Days 1 and 8 of Cycle 3, and Day 1 of Cycles 4 and 8

  11. Part 1: Incidence of Antidrug Antibodies (ADA) to Sacituzumab Tirumotecan

    Blood samples collected at designated timepoints will be used to determine the ADA response to sacituzumab tirumotecan. The incidence of ADAs over time in Part 1 will be presented.

    Time frame: Day 1 of Cycles 1 (each cycle is 21 days), 2, 3, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  12. Part 1: Incidence of ADA to Enfortumab Vedotin

    Blood samples collected at designated timepoints will be used to determine the ADA response to sacituzumab tirumotecan. The incidence of ADAs over time in Part 1 will be presented.

    Time frame: Day 1 of Cycles 1 (each cycle is 21 days), 2, 3, 4 and 8

  13. Part 2: Cmax of Sacituzumab Tirumotecan-ADC

    Blood samples collected at designated time points will be used to determine the Cmax of sacituzumab tirumotecan-ADC in Part 2.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  14. Part 2: Ctrough of Sacituzumab Tirumotecan-ADC

    Blood samples collected at designated time points will be used to determine the Ctrough of sacituzumab tirumotecan-ADC in Part 2.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  15. Part 2: Cmax of Free Payload for Sacituzumab Tirumotecan

    Blood samples collected at designated time points will be used to determine the Cmax of free payload for sacituzumab tirumotecan in Part 2.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  16. Part 2: Ctrough of Free Payload for Sacituzumab Tirumotecan

    Blood samples collected at designated time points will be used to determine the Ctrough of free payload for sacituzumab tirumotecan in Part 2.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  17. Part 2: Cmax of Enfortumab Vedotin-ADC

    Blood samples collected at designated time points will be used to determine the Cmax of enfortumab vedotin-ADC in Part 2.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8

  18. Part 2: Ctrough of Enfortumab Vedotin-ADC

    Blood samples collected at designated time points will be used to determine the Ctrough of enfortumab vedotin-ADC in Part 2.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8

  19. Part 2: Cmax of Free Payload for Enfortumab Vedotin

    Blood samples collected at designated time points will be used to determine the Cmax of free payload for EV in Part 2.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8

  20. Part 2: Ctrough of Free Payload for Enfortumab Vedotin

    Blood samples collected at designated time points will be used to determine the Ctrough of free payload for EV in Part 2.

    Time frame: Days 1 and 8 of Cycle 1 (each cycle is 21 days), Day 1 of Cycles 2, 4 and 8

  21. Part 2: Cmax of Pembrolizumab-ADC

    Blood samples collected at designated time points will be used to determine the Cmax of pembrolizumab-ADC.

    Time frame: Days 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  22. Part 2: Ctrough of Pembrolizumab-ADC

    Blood samples collected at designated time points will be used to determine the Ctrough of pembrolizumab-ADC.

    Time frame: Days 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  23. Part 2: Cmax of Free Payload for Pembrolizumab

    Blood samples collected at designated time points will be used to determine the Cmax of free payload for pembrolizumab.

    Time frame: Days 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  24. Part 2: Ctrough of Free Payload for Pembrolizumab

    Blood samples collected at designated time points will be used to determine the Ctrough of free payload for pembrolizumab.

    Time frame: Days 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  25. Part 2: Incidence of ADA to Sacituzumab Tirumotecan

    Blood samples collected at designated timepoints will be used to determine the ADA response to sacituzumab tirumotecan. The incidence of ADAs over time in Part 2 will be presented.

    Time frame: Day 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

  26. Part 2: Incidence of ADA to Enfortumab Vedotin

    Blood samples collected at designated timepoints will be used to determine the ADA response to EV. The incidence of ADAs over time in Part 2 will be presented.

    Time frame: Day 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8

  27. Part 2: Incidence of ADA to Pembrolizumab

    Blood samples collected at designated timepoints will be used to determine the ADA response to pembrolizumab. The incidence of ADAs over time be presented.

    Time frame: Day 1 of Cycles 1 (each cycle is 21 days), 2, 4 and 8 and every 4 cycles thereafter up to Cycle 35, at end of treatment, and at 30 days post last dose

07

Study locations

25 sites
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2028, 44 months after the start.

Of 47 phase 1/2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 224. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2024
First posted
Jul 3, 2024
StartActual
Jul 17, 2024
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06483334
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Jul 17, 2024
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Feb 18, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacituzumab tirumotecan · Enfortumab vedotin

Start the discussion